Common Acne Medication Linked With 30% Lower Schizophrenia Risk

An antibiotic frequently used to treat acne has been associated with a lower likelihood of later developing schizophrenia.

Researchers at the University of Edinburgh report that, among adolescents who had accessed mental health services, those who were prescribed doxycycline were less often diagnosed with schizophrenia as adults than those who received other classes of antibiotic.

Although these early results do not demonstrate that doxycycline prevents schizophrenia, the team suggests the drug’s known effects on immune responses, inflammation, and programmed cell death could, in theory, help to avert neurological changes thought to contribute to the condition.

The authors stress that the evidence is observational and therefore cannot establish cause and effect. They conclude that further work is required, while noting that the findings open a tentative yet promising avenue for future research into preventing severe mental illness.

Schizophrenia, psychosis, and gaps in care

Schizophrenia is a serious mental health condition affecting around 23 million people globally, with diagnoses most commonly made in the late teens or twenties.

It may begin abruptly and lead to psychosis. Typical features include persistent delusions, hallucinations, disorganised thinking, marked agitation, and social withdrawal.

According to the World Health Organization (WHO), over two in three people experiencing psychosis do not receive specialist mental health care.

Doxycycline for acne vulgaris and possible neuroprotective effects

Doxycycline is a broad-spectrum antibiotic commonly prescribed to adolescents for acne vulgaris. Interest in the drug has grown because some studies indicate it may have neuroprotective properties, including the ability to cross the blood–brain barrier.

Supporting this broader line of enquiry, a 2024 Danish study reported that this brain-penetrating antibiotic was associated with a markedly lower incidence rate of receiving a disability pension among people with schizophrenia-an outcome used as a proxy for how strongly the condition can affect everyday functioning.

University of Edinburgh analysis in Finland: doxycycline and schizophrenia risk

To examine the association more closely, child and adolescent psychiatrist Ian Kelleher of the University of Edinburgh led an international team analysing health records for more than 56,000 people born in Finland between 1987 and 1997. All had used mental health services during adolescence and had also been prescribed antibiotics earlier in life.

Across the subsequent decade, individuals treated with doxycycline showed a 30–35% lower risk of developing schizophrenia than peers given other antibiotics. In absolute terms, the estimated likelihood fell from 2.1% among those taking other antibiotics to 1.4% among those who took doxycycline.

How might an antibiotic influence schizophrenia?

One possibility raised by the researchers is that doxycycline reduces an infectious burden in the body-and potentially the brain-that could contribute to schizophrenia risk. Another is that the drug directly alters brain inflammation or neural circuitry (“brain wiring”) in a way that lowers vulnerability.

Evidence from work with other antibiotics offers related clues. In a 2019 study using stem cells derived from people with schizophrenia and from healthy volunteers, minocycline was found to reduce excessive synaptic pruning-the trimming back of connections between nerve cells-which has been implicated in schizophrenia.

Because minocycline and doxycycline are both tetracycline antibiotics, the authors note that shared biological actions could partly explain why doxycycline might be linked to lower schizophrenia risk.

Why adolescence may be a key window for prevention

Using Finnish health data, Kelleher and colleagues observed that close to half of psychotic disorders diagnosed in the wider population occurred in people who had already attended psychiatric services during adolescence.

They argue this stage may represent a practical opportunity to intervene, potentially using medicines such as doxycycline to reduce the chance that early mental health problems progress towards schizophrenia.

“As many as half of the people who develop schizophrenia had previously attended child and adolescent mental health services for other mental health problems,” Kelleher says. “At present, though, we don’t have any interventions that are known to reduce the risk of going on to develop schizophrenia in these young people. That makes these findings exciting.”

What these findings do-and do not-mean

Because the study relies on observational data, it cannot rule out alternative explanations such as differences in underlying health, infection patterns, prescribing practices, or other treatments received by those given doxycycline. The researchers therefore emphasise that the results should be treated as provisional until tested using stronger designs.

If future studies explore doxycycline as a preventive approach, they will also need to balance potential benefits against recognised concerns associated with antibiotic use, including side effects and the wider public-health issue of antimicrobial resistance. Determining the appropriate patients, timing, and duration of any treatment would be essential before clinical practice could change.

The study was published in the American Journal of Psychiatry.